Biogen Inc

2026. g. 26. jūn. 19:51 UTC

Biogen Inc pauses investment in most legacy Apellis programs, aligning with current objectives. Shares are higher today, reflecting positive investor response to the restructuring.

2026. g. 25. jūn. 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting a notable upward trajectory since Thursday's close amid mixed broader market results.

2026. g. 24. jūn. 20:04 UTC

Biogen Inc shares are higher today, supported by a broader rally in the Biotechnology sector and increased interest noted on social media.

2026. g. 23. jūn. 23:21 UTC

Biogen Inc shares are higher in after-market trading, reaching a session high. No specific news was identified to explain the unusual price movement.

2026. g. 22. jūn. 23:46 UTC

Biogen Inc. shares traded lower in after-market hours following modest fluctuations since Monday's close, with the price dipping after a brief session high.

2026. g. 18. jūn. 20:05 UTC

Biogen Inc. plans to acquire RayThera Inc. for up to $1 billion, but shares are declining amid broader Biotechnology sector weakness.

2026. g. 17. jūn. 23:06 UTC

Biogen Inc announced a definitive agreement to acquire RayThera Inc. for up to $1 billion, enhancing its immunology pipeline. Shares are trading higher after the news.

2026. g. 16. jūn. 19:46 UTC

Biogen Inc. shares are lower amid an investigation announcement linked to the Phase 2 CELIA study's failure and failed negotiations over Skyclarys.

2026. g. 12. jūn. 19:51 UTC

Biogen Inc. shares are higher today, breaking a recent trend. Broader market sentiment is shaped by inflation concerns and optimism about upcoming IPOs.

2026. g. 11. jūn. 19:51 UTC

Biogen Inc is advancing as the biotechnology sector gains. Earlier in the session, shares pulled back from a high but resumed their upward trajectory.

2026. g. 10. jūn. 19:36 UTC

Biogen Inc. is under investigation by Bronstein, Gewirtz & Grossman, LLC, following disappointing Phase 2 CELIA study results. Shares are trading lower amid ongoing scrutiny.

2026. g. 9. jūn. 23:16 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Tuesday's close. The asset remains above its 20-day moving average.

2026. g. 8. jūn. 20:06 UTC

Biogen Inc. shares are lower amid negative sentiment over its Phase 2 CELIA study results, despite a recent upgrade to a Buy rating.

2026. g. 5. jūn. 19:16 UTC

Biogen shares are gaining following FDA's Breakthrough Therapy Designation for salanersen in spinal muscular atrophy, despite pulling back from earlier session highs.

2026. g. 4. jūn. 22:06 UTC

Biogen Inc. received FDA Breakthrough Therapy Designation for salanersen, aimed at treating spinal muscular atrophy, with shares trading higher in after-market hours.

2026. g. 3. jūn. 20:03 UTC

Biogen Inc. announced fourteen abstracts accepted for presentation at upcoming nephrology congresses, contributing to higher trading shares amid positive market sentiment.

2026. g. 2. jūn. 20:06 UTC

Biogen Inc. shares declined during Tuesday's session, continuing a trend of lower closes, amid broader weakness in the biotechnology sector.

2026. g. 1. jūn. 19:26 UTC

Biogen shares are lower following positive Phase 3 trial results for dapirolizumab pegol, despite significant improvements in disease activity for lupus patients.

2026. g. 29. maijs 19:26 UTC

Biogen Inc. shares are trading lower today, reversing a recent trend of higher daily closes since Thursday's close. No specific news was identified.

2026. g. 28. maijs 20:06 UTC

Biogen Inc shares are lower, continuing a downward trend since Wednesday. No specific news was identified to explain today's movement.

2026. g. 27. maijs 20:06 UTC

RBC Capital raised its price target on Biogen Inc to $227, supporting shares' overall gain during Wednesday's trading amid positive pipeline developments.

2026. g. 26. maijs 19:56 UTC

Biogen Inc. shares are lower following concerns over the failure of its Parkinson's drug BIIB122 in a Phase 2b trial.

2026. g. 22. maijs 19:37 UTC

Biogen shares are higher following the Phase 2b LUMA study results for BIIB122, which showed over 90% kinase inhibition despite not meeting primary endpoints.

2026. g. 21. maijs 23:02 UTC

Biogen Inc. shares declined in after-market hours following the failure of its Parkinson's treatment, BIIB122, to meet key trial endpoints in the Phase 2b LUMA study.

2026. g. 20. maijs 23:51 UTC

Biogen Inc. shares are trading lower in after-market hours, reflecting broader market declines amid weak sentiment and macroeconomic factors affecting various sectors.

2026. g. 19. maijs 23:36 UTC

Biogen Inc shares are trading higher in after-market hours, showing a modest recovery from earlier losses amid broader market caution over inflationary pressures.

2026. g. 18. maijs 19:15 UTC

Biogen shares are lower amid negative sentiment from its CELIA trial results, which failed to meet primary endpoints, and ongoing investigations into potential securities violations.

2026. g. 15. maijs 19:56 UTC

Biogen completes $5.3 billion acquisition of Apellis Pharmaceuticals, enhancing its drug portfolio. Shares are trading higher amid positive analyst ratings and target price increases.

2026. g. 14. maijs 23:01 UTC

Biogen shares rose in after-market hours following positive topline results from the Phase 2 CELIA study on diranersen for early Alzheimer's disease.